Marksans Pharma (NSE:MARKSANS) Interest Expense : ₹-54 Mil (TTM As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Marksans Pharma's interest expense for the three months ended in Dec. 2023 was ₹ -32 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-54 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Marksans Pharma's Operating Income for the three months ended in Dec. 2023 was ₹ 1,110 Mil. Marksans Pharma's Interest Expense for the three months ended in Dec. 2023 was ₹ -32 Mil. Marksans Pharma's Interest Coverage for the quarter that ended in Dec. 2023 was 35.12. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Marksans Pharma Interest Expense Historical Data

The historical data trend for Marksans Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma Interest Expense Chart

Marksans Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-59.25

-49.70

-34.67

-53.90

-57.46

Marksans Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-23.52	9.42	-15.76	-16.26	-31.61

Marksans Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-54 Mil.

Marksans Pharma (NSE:MARKSANS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Marksans Pharma's Interest Expense for the three months ended in Dec. 2023 was ₹-32 Mil. Its Operating Income for the three months ended in Dec. 2023 was ₹1,110 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was ₹0 Mil.

Marksans Pharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	1110.19	/	-31.61
	=	35.12

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Marksans Pharma Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Marksans Pharma (NSE:MARKSANS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

524404:India

Address

Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053

Website

http://www.marksanspharma.com

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines